Elie Fahed, MD: I was waiting to get my paperwork in order, and you were seeing a local doctor, Dr. Alan Grosset. He was helping you, and he did the bone marrow biopsy and then the MRI. Mark Ayen: He ...

Is low-dose cyclophosphamide (Cy) plus G-CSF (G) mobilization as effective as plerixafor plus G in multiple myeloma (MM) patients (pts) who are candidates for tandem autologous transplants (autoT)?

Therapy-related B-lymphoblastic leukemia (B-ALL) following treatment for multiple myeloma is a rare occurrence. Despite its rarity and the lack of recognition by the World Health Organization as a ...

Free light chains, kappa (κ) lambda (λ), are produced by plasma cells and known to be an important marker in patients with Multiple Myeloma and AL Amyloidosis. The precursor condition to Multiple ...

Normalization of the serum-free light-chain ratio (FLCr) with the absence of bone marrow monoclonal plasma cells following achievement of a complete response (CR) to therapy denotes a stringent CR in ...

While multiple myeloma tends to impact the kidneys in all patients, this subset with excessive light chains appears to have worse damage, Singh says. An important bottom line is shorter survival, he ...

Background: Monoclonal free light chains (FLCs) frequently cause rapidly progressive renal failure in patients with multiple myeloma. Immunoassays which provide quantitative measurement of FLCs in ...

The demographics and selected assay results for the patients are presented in Table 1. There were no significant differences in the demographics of the AKI patients with and without myeloma. The ...